Dopaminergic regulation of prolactin secretion in the hyperprolactinemic syndrome.
The prolactin responses to an oral challenge of L-dopa (0.5 g) and bromocriptine (2.5 mg) were studied in 31 hyperprolactinemic females without radiological abnormalities of pituitary fossa, in 12 hyperprolactinemic patients with minor radiological evidence suggesting the presence of a pituitary adenoma and in 16 normal volunteers in the early puerperium with physiological hyperprolactinemia. Administration of bromocriptine was followed by a similar suppression of prolactin secretion in the functional as well as the adenomatous hyperprolactinemic patients. By contrast, a significantly blunted response to L-dopa was noted in the patients with pathological hyperprolactinemia (with and without radiological abnormalities of the pituitary fossa). These results suggest that the L-dopa suppression test might serve as a reliable indicator to detect prolactin-secreting microadenomas in patients with persistent hyperprolactinemia and radiologically normal pituitary fossae.
D000236:Adenoma / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000097:blood; D010902:Pituitary Gland / Q000000981:diagnostic imaging; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D011388:Prolactin / Q000097:blood*; D011859:Radiography; D013577:Syndrome
D001971:Bromocriptine; D007980:Levodopa; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone